Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus

International Journal of Clinical Practice

Volumn 69, Issue 5, 2015, Pages 550-559

  Garcia Egido, A ^a   Andrey, J L ^a   Puerto, J L ^a   Aranda, R M ^a   Pedrosa, M J ^a   Lopez Saez J B ^a   Rosety, M ^a   Gomez, F ^a  

^a HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NITRIC ACID DERIVATIVE; SITAGLIPTIN; SULFONYLUREA; VASODILATOR AGENT; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART FAILURE; HEART FAILURE WITH DEPRESSED EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; PROPENSITY SCORE; PROSPECTIVE STUDY; RISK REDUCTION; SEX RATIO; CASE CONTROL STUDY; COMPLICATION; MORTALITY; SEVERITY OF ILLNESS INDEX; SPAIN;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; BISOPROLOL; CARBAZOLES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HUMANS; MALE; PROGNOSIS; PROPANOLAMINES; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 84928585543     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12567     Document Type: Article

References (32)

1. Haas SJ, Vos T, Gilbert RE, Krum H,. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003; 146: 848-53.
2. Subramanian U, Kamalesh M, Temkit M, Eckert GJ, Sawada S,. Do cardioselective beta-adrenoceptor antagonists reduce mortality in diabetic patients with congestive heart failure? Am J Cardiovasc Drugs 2009; 9: 231-40.
3. de Boer RA, Doehner W, van der Horst IC, et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients ≥70 years old with heart failure and effects of nevibolol (Data from the Study of Effects of Nevibolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). Am J Cardiol 2010; 106: 78-86.
4. Bobio M, Ferrua S, Opasich C, et al. Survival and hospitalization in heart failure patients with or without diabetes treated with β-blockers. J Cardiac Fail 2003; 9: 192-202.
5. Smith DT, Farzaneh-Far R, Ali S, Na B, Whooley MA, Schiller NB,. Relation of beta blocker use with frequency of hospitalization for heart failure in patients with left ventricular diastolic dysfunction (From the Heart and Soul Study). Am J Cardiol 2010; 105: 223-8.
6. Del Sindaco D, Pulignano G, Cioffi G, et al. Safety and efficacy of carvedilol in very elderly patients with heart failure. J Cardiovasc Med 2007; 8: 675-82.
7. Gomez-Soto FM, Andrey JL, Garcia-Egido AA, et al. Incidence and mortality of heart failure: a community-based study. Int J Cardiol 2011; 151: 40-5.
8. Gomez-Soto FM, Puerto JL, Andrey JL, Fernandez FJ, Bernal JA, Gomez F,; for the "Grupo para la Atenciõn Médica Integral y Contínua" of Cádiz (GAMIC). Consultation between specialists in Internal Medicine and Family Medicine improves management and prognosis of heart failure. Eur J Intern Med 2008; 19: 548-54.
9. McKee PA, Castelli WP, McNamara PM, Kannel WB,. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-6.
10. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG,. Using serum creatinine glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004; 141: 929-37.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic morbidity in longitudinal studies: development and validation. Chronic Dis 1987; 40: 373-83.
12. Mottram PM, Marwick TH,. Assessment of diastolic function: what the general cardiologist needs to know. Heart 2005; 91: 681-95.
13. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KB, Rodeheffer RJ,. Burden of systolic and diastolic ventricular dysfunction in the community. Appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011; 34 (Suppl. 1): S62-9.
15. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
16. MacDonald MR, Petrie MC, Hawkins NH, et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008; 29: 1224-40.
17. Kamalesh M,. Heart failure in diabetes and related conditions. J Cardiac Fail 2007; 13: 861-73.
18. MacDonald MR, Eurich DT, Majumdar SR, et al. Treatment of diabetes mellitus and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 2010; 33: 1213-8.
19. Ray JG, Gong Y, Sykora K, Tu JV,. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005; 165: 62-7.
20. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH,. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006; 296: 2105-11.
21. Rubin DB,. On principles for modelling propensity scores in medical research. Pharmacoepidemiol Drug Saf 2004; 13: 855-7.
22. A'Agostino RB Jr,. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-81.
23. Rosenbaum PR,. Sensitivity analysis for matching with multiple controls. Biometrika 1988; 75: 577-81.
24. Lee D, Austin P, Rouleau J, Liu P, Naimark D, Tu J,. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290: 2581-7.
25. Call KL, Craddock D, Edwards K,. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis. Pharmacotherapy 2006; 9: 1297-306.
26. Andren L,. General considerations in selecting antihypertensive agents in patients with type II diabetes mellitus and hypertension. Am J Med 1989; 87: 39S-41S.
27. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM,. Thiazolidinedines, metformin outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583-90.
28. Therneau TM, Grambsch PM,. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer, 2000.
29. Messerli FH, Bangalore S, Julius S,. Risk/benefit assessment of b-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008; 117: 2706-15.
30. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-36.
31. Heinemann L, Heise T, Ampudia J, et al. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity. Eur J Clin Invest 1995; 25: 595-600.
32. Piña IL, O'Connor C,. BNP-guided therapy for heart failure. JAMA 2009; 301: 432-4.